The 10 that are cited most themselves, of 61.
Judgment of the General Court (Seventh Chamber, Extended Composition) of 5 May 2021. Pharmaceutical Works Polpharma S.A. v European MedicineDecision
On 28 February 2012, Biogen Idec submitted to the EMA an application for marketing authorisation for Tecfidera – Dimethyl fumarate (‘Tecfidera – Dimethyl fumarate’ or ‘Tecfidera’), a medicinal product for human use, in …
5 May 2021 · 62018TJ0611
Judgment of the Court (Fourth Chamber) of 16 March 2023. European Commission and Others v Pharmaceutical Works Polpharma S.A.Decision
Article 4(1) of that regulation provides: ‘Applications for the marketing authorisations referred to in Article 3 shall be submitted to the [EMA].’
16 Mar 2023 · 62021CJ0438
Order of the President of the General Court of 4 August 2022. Biogen Netherlands BV v European Commission.Decision
On 28 February 2012, Biogen Idec Limited lodged with the European Medicines Agency (EMA) an application for marketing authorisation, pursuant to Article 4(1) of Regulation (EC) No 726/2004 of the European Parliament and of the Council of …
4 Aug 2022 · 62022TO0278
Order of the President of the General Court of 4 August 2022. Biogen Netherlands BV v European Commission.Decision
On 28 February 2012, Biogen Idec Limited lodged with the European Medicines Agency (EMA) an application for marketing authorisation, pursuant to Article 4(1) of Regulation (EC) No 726/2004 of the European Parliament and of the Council of …
4 Aug 2022 · 62022TO0269
Order of the President of the General Court of 4 August 2022. Biogen Netherlands BV v European Commission.Decision
On 28 February 2012, Biogen Idec Limited lodged with the European Medicines Agency (EMA) an application for marketing authorisation, pursuant to Article 4(1) of Regulation (EC) No 726/2004 of the European Parliament and of the Council of …
4 Aug 2022 · 62022TO0279
Order of the Court (Eighth Chamber) of 14 May 2012. Sepracor Pharmaceuticals (Ireland) Ltd v European Commission.Decision
14 May 2012 · 62011CO0477
Judgment of the General Court (Sixth Chamber) of 19 December 2019. Vanda Pharmaceuticals Ltd v European Commission.Decision
On 4 December 2015 the applicant, pursuant to Article 4 of Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal …
19 Dec 2019 · 62018TJ0211
Regulation (EU) 2019/5Lawamends
Judgment of the General Court (Second Chamber) of 15 September 2015. Novartis Europharm Ltd v European Commission.Decision
… киселина“ (наричан по-нататък „Zoledronic acid Teva Pharma“) на основание член 4, параграф 1 от Регламент № 726/2004.
15 Sep 2015 · 62012TJ0472
Order of the President of the General Court of 29 February 2024. Neuraxpharm Pharmaceuticals SL v European Commission.Decision
On 28 February 2012, Biogen Idec Ltd filed an application with the European Medicines Agency (EMA), pursuant to Article 4(1) of Regulation No 726/2004, for a marketing authorisation (‘MA’) for the medicinal product ‘Tecfidera – …
29 Feb 2024 · 62023TO1182